UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.115

Sortiert nach

Review: Placental adaptations to the presence of maternal asthma during pregnancy

Placenta (Eastbourne), 2017-06, Vol.54, p.17-23

2017

Volltextzugriff (PDF)

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity

British journal of pharmacology, 2010-11, Vol.161 (5), p.1099-1110

2010

Volltextzugriff (PDF)

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

Drug metabolism and disposition, 2022-04, Vol.50 (4), p.327-340

2022

Volltextzugriff (PDF)

Assessing the visual quality of rural landscapes

Landscape and urban planning, 2004-07, Vol.69 (1), p.115-125

2004

Volltextzugriff (PDF)

Evaluation of different configurations of hybrid membrane bioreactors for treatment of domestic wastewater

Water science and technology, 2015-01, Vol.71 (3), p.338

2015

Volltextzugriff (PDF)

Development of a new method for the quantitation of metabolites in the absence of chemically synthetized authentic standards

Journal of pharmaceutical and biomedical analysis, 2019-05, Vol.169, p.70-74

2019

Volltextzugriff (PDF)

55 Low, frequent doses of PM060184 induce remarkable in vivo antitumor activity

European journal of cancer (1990), 2014-11, Vol.50, p.23-23

2014

Volltextzugriff (PDF)

220 Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models

European journal of cancer (1990), 2012-11, Vol.48, p.66-67

2012

Volltextzugriff (PDF)

896 Antitumor Effect of PM01183 in a Patient-Derived Cisplatin-Sensitive and -Resistant Serous Epithelial Ovarian Orthotopic Tumor Model

European journal of cancer (1990), 2012-07, Vol.48, p.S217-S217

2012

Volltextzugriff (PDF)

223 Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts

European journal of cancer (1990), 2012-11, Vol.48, p.67-68

2012

Volltextzugriff (PDF)

222 Lurbinectedin (PM01183): Pharmacokinetics/Pharmacodynamic (PK/PD) Properties in Pancreas, Ovarian and NSCLC Xenografts

European journal of cancer (1990), 2012-11, Vol.48, p.67-67

2012

Volltextzugriff (PDF)

221 Lurbinectedin (PM01183) in Combination with Gemcitabine in Patient-Derived, Pancreatic Ductal Adenocarcinoma (PDA) Xenografts

European journal of cancer (1990), 2012-11, Vol.48, p.67-67

2012

Volltextzugriff (PDF)

Use of air stacking and abdominal compression for cough assistance in people with complete tetraplegia

Spinal cord, 2014-05, Vol.52 (5), p.354-357

2014

Volltextzugriff (PDF)

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the VSL and the BIPM

Metrologia, 2024-01, Vol.61 (1A), p.6010

2024

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal Candidiasis

Antimicrobial Agents and Chemotherapy, 2000-09, Vol.44 (9), p.2333-2340

2000

Volltextzugriff (PDF)

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

Journal of pharmaceutical and biomedical analysis, 2018-09, Vol.158, p.160-165

2018

Volltextzugriff (PDF)

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

Journal of pharmaceutical and biomedical analysis, 2017-10, Vol.145, p.137-143

2017

Volltextzugriff (PDF)

Key comparisons of air kerma and absorbed dose to water standards in 60 Co radiation beam (EURAMET.RI(I)-K1.3 and EURAMET.RI(I)-K4.3)

Metrologia, 2023-01, Vol.60 (1A), p.6023

2023

Volltextzugriff (PDF)

Key comparisons of air kerma and absorbed dose to water standards in 60Co radiation beam (EURAMET.RI(I)-K1.3 and EURAMET.RI(I)-K4.3)

Metrologia, 2023-01, Vol.60 (1A), p.06023

2023

Volltextzugriff (PDF)

Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis

Antimicrobial Agents and Chemotherapy, 2000-12, Vol.44 (12), p.3389-3394

2000

Volltextzugriff (PDF)

A multi-objective evolutionary approach for planning and optimal condition restoration of secondary distribution networks

Applied soft computing, 2020-05, Vol.90, p.106182, Article 106182

2020

Volltextzugriff (PDF)

Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization

Journal of biomedical nanotechnology, 2012-08, Vol.8 (4), p.703

2012

Volltextzugriff (PDF)

Evaluation of risk of deterministic effects in fluoroscopically guided procedures

Radiation protection dosimetry, 2005-01, Vol.117 (1-3), p.190-194

2005

Volltextzugriff (PDF)

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

Cancer chemotherapy and pharmacology, 2018-09, Vol.82 (3), p.441-455

2018

Volltextzugriff (PDF)

1 – 25 von 1.115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(959)
Mit Volltextzugriff
(988)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Review: Placental adaptations to the presence of maternal asthma during pregnancy

S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

Assessing the visual quality of rural landscapes

Evaluation of different configurations of hybrid membrane bioreactors for treatment of domestic wastewater

Development of a new method for the quantitation of metabolites in the absence of chemically synthetized authentic standards

55 Low, frequent doses of PM060184 induce remarkable in vivo antitumor activity

220 Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models

896 Antitumor Effect of PM01183 in a Patient-Derived Cisplatin-Sensitive and -Resistant Serous Epithelial Ovarian Orthotopic Tumor Model

223 Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts

222 Lurbinectedin (PM01183): Pharmacokinetics/Pharmacodynamic (PK/PD) Properties in Pancreas, Ovarian and NSCLC Xenografts

221 Lurbinectedin (PM01183) in Combination with Gemcitabine in Patient-Derived, Pancreatic Ductal Adenocarcinoma (PDA) Xenografts

Use of air stacking and abdominal compression for cough assistance in people with complete tetraplegia

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the VSL and the BIPM

Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal Candidiasis

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

Key comparisons of air kerma and absorbed dose to water standards in 60 Co radiation beam (EURAMET.RI(I)-K1.3 and EURAMET.RI(I)-K4.3)

Key comparisons of air kerma and absorbed dose to water standards in 60Co radiation beam (EURAMET.RI(I)-K1.3 and EURAMET.RI(I)-K4.3)

Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis

A multi-objective evolutionary approach for planning and optimal condition restoration of secondary distribution networks

Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization

Evaluation of risk of deterministic effects in fluoroscopically guided procedures

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

Suchergebnisse filtern